Statin use and Parkinson's disease in Denmark
Identifieur interne : 000535 ( Main/Exploration ); précédent : 000534; suivant : 000536Statin use and Parkinson's disease in Denmark
Auteurs : Beate Ritz [États-Unis] ; Angelika D. Manthripragada [États-Unis] ; Lei Qian [États-Unis] ; Eva Schernhammer [États-Unis] ; Lene Wermuth [Danemark] ; Jorgen Olsen [Danemark] ; Soren Friis [Danemark]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-07-15.
English descriptors
Abstract
The objective of this study was to investigate whether statin (3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase inhibitor) use is associated with risk of Parkinson's disease (PD) in Denmark. We identified 1,931 patients with a first time diagnosis of PD reported in hospital or outpatient clinic records between 2001 and 2006. We density matched to these patients 9,651 population controls by birth year and sex relying on the Danish population register. For every participant, we identified pharmacy records of statin and anti‐Parkinson drug prescriptions since 1995 and before index date from a prescription medication use database for all Danish residents. Whenever applicable, the index dates for cases and their corresponding controls were advanced to the date of first recorded prescription for anti‐Parkinson drugs. In our primary analyses, we excluded all statin prescriptions 2‐years before PD diagnosis. Employing logistic regression adjusting for age, sex, diagnosis of chronic obstructive pulmonary disease, and Charlson comorbidity, we observed none to slightly inverse associations between PD diagnosis and statin prescription drug use. Inverse associations with statin use were only observed for short‐term (≤1 yrs) statin users (2‐year lag OR 0.57; 95% CI 0.36 to 0.89); and suggested at higher intensity statin use (2‐year lag OR 0.69; 95% CI 0.45–1.04). No associations were seen among long‐term users and no difference by sex, age, or type of statins used (lipophilic/hydrophilic). We found little evidence for a neuroprotective role of statins in PD except for short‐term or high intensity users. Yet, further investigations into the contributions of intensity, duration, and lag periods of statin use may still be warranted. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23102
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Statin use and Parkinson's disease in Denmark</title><author><name sortKey="Ritz, Beate" sort="Ritz, Beate" uniqKey="Ritz B" first="Beate" last="Ritz">Beate Ritz</name></author><author><name sortKey="Manthripragada, Angelika D" sort="Manthripragada, Angelika D" uniqKey="Manthripragada A" first="Angelika D." last="Manthripragada">Angelika D. Manthripragada</name></author><author><name sortKey="Qian, Lei" sort="Qian, Lei" uniqKey="Qian L" first="Lei" last="Qian">Lei Qian</name></author><author><name sortKey="Schernhammer, Eva" sort="Schernhammer, Eva" uniqKey="Schernhammer E" first="Eva" last="Schernhammer">Eva Schernhammer</name></author><author><name sortKey="Wermuth, Lene" sort="Wermuth, Lene" uniqKey="Wermuth L" first="Lene" last="Wermuth">Lene Wermuth</name></author><author><name sortKey="Olsen, Jorgen" sort="Olsen, Jorgen" uniqKey="Olsen J" first="Jorgen" last="Olsen">Jorgen Olsen</name></author><author><name sortKey="Friis, Soren" sort="Friis, Soren" uniqKey="Friis S" first="Soren" last="Friis">Soren Friis</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3EC6C080C582D67764314AA87F2018A2A13C107B</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23102</idno><idno type="url">https://api.istex.fr/document/3EC6C080C582D67764314AA87F2018A2A13C107B/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000343</idno><idno type="wicri:Area/Main/Curation">000294</idno><idno type="wicri:Area/Main/Exploration">000535</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Statin use and Parkinson's disease in Denmark</title><author><name sortKey="Ritz, Beate" sort="Ritz, Beate" uniqKey="Ritz B" first="Beate" last="Ritz">Beate Ritz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, UCLA School of Public Health, Los Angeles, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Manthripragada, Angelika D" sort="Manthripragada, Angelika D" uniqKey="Manthripragada A" first="Angelika D." last="Manthripragada">Angelika D. Manthripragada</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, UCLA School of Public Health, Los Angeles, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Qian, Lei" sort="Qian, Lei" uniqKey="Qian L" first="Lei" last="Qian">Lei Qian</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics, UCLA School of Public Health, Los Angeles, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Schernhammer, Eva" sort="Schernhammer, Eva" uniqKey="Schernhammer E" first="Eva" last="Schernhammer">Eva Schernhammer</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Channing Laboratory, Department of Medicine, Harvard Medical School, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Wermuth, Lene" sort="Wermuth, Lene" uniqKey="Wermuth L" first="Lene" last="Wermuth">Lene Wermuth</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Neurology, Odense University Hospital, Odense</wicri:regionArea><wicri:noRegion>Odense</wicri:noRegion></affiliation></author><author><name sortKey="Olsen, Jorgen" sort="Olsen, Jorgen" uniqKey="Olsen J" first="Jorgen" last="Olsen">Jorgen Olsen</name><affiliation wicri:level="3"><country xml:lang="fr">Danemark</country><wicri:regionArea>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Friis, Soren" sort="Friis, Soren" uniqKey="Friis S" first="Soren" last="Friis">Soren Friis</name><affiliation wicri:level="3"><country xml:lang="fr">Danemark</country><wicri:regionArea>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-07-15">2010-07-15</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1210">1210</biblScope><biblScope unit="page" to="1216">1216</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">3EC6C080C582D67764314AA87F2018A2A13C107B</idno><idno type="DOI">10.1002/mds.23102</idno><idno type="ArticleID">MDS23102</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>pharmacy</term><term>pharmocoepidemiology</term><term>record study</term><term>statin use</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study was to investigate whether statin (3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase inhibitor) use is associated with risk of Parkinson's disease (PD) in Denmark. We identified 1,931 patients with a first time diagnosis of PD reported in hospital or outpatient clinic records between 2001 and 2006. We density matched to these patients 9,651 population controls by birth year and sex relying on the Danish population register. For every participant, we identified pharmacy records of statin and anti‐Parkinson drug prescriptions since 1995 and before index date from a prescription medication use database for all Danish residents. Whenever applicable, the index dates for cases and their corresponding controls were advanced to the date of first recorded prescription for anti‐Parkinson drugs. In our primary analyses, we excluded all statin prescriptions 2‐years before PD diagnosis. Employing logistic regression adjusting for age, sex, diagnosis of chronic obstructive pulmonary disease, and Charlson comorbidity, we observed none to slightly inverse associations between PD diagnosis and statin prescription drug use. Inverse associations with statin use were only observed for short‐term (≤1 yrs) statin users (2‐year lag OR 0.57; 95% CI 0.36 to 0.89); and suggested at higher intensity statin use (2‐year lag OR 0.69; 95% CI 0.45–1.04). No associations were seen among long‐term users and no difference by sex, age, or type of statins used (lipophilic/hydrophilic). We found little evidence for a neuroprotective role of statins in PD except for short‐term or high intensity users. Yet, further investigations into the contributions of intensity, duration, and lag periods of statin use may still be warranted. © 2010 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Danemark</li><li>États-Unis</li></country><region><li>Californie</li><li>Hovedstaden</li><li>Massachusetts</li></region><settlement><li>Copenhague</li></settlement></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Ritz, Beate" sort="Ritz, Beate" uniqKey="Ritz B" first="Beate" last="Ritz">Beate Ritz</name></region><name sortKey="Manthripragada, Angelika D" sort="Manthripragada, Angelika D" uniqKey="Manthripragada A" first="Angelika D." last="Manthripragada">Angelika D. Manthripragada</name><name sortKey="Qian, Lei" sort="Qian, Lei" uniqKey="Qian L" first="Lei" last="Qian">Lei Qian</name><name sortKey="Schernhammer, Eva" sort="Schernhammer, Eva" uniqKey="Schernhammer E" first="Eva" last="Schernhammer">Eva Schernhammer</name></country><country name="Danemark"><noRegion><name sortKey="Wermuth, Lene" sort="Wermuth, Lene" uniqKey="Wermuth L" first="Lene" last="Wermuth">Lene Wermuth</name></noRegion><name sortKey="Friis, Soren" sort="Friis, Soren" uniqKey="Friis S" first="Soren" last="Friis">Soren Friis</name><name sortKey="Olsen, Jorgen" sort="Olsen, Jorgen" uniqKey="Olsen J" first="Jorgen" last="Olsen">Jorgen Olsen</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000535 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000535 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:3EC6C080C582D67764314AA87F2018A2A13C107B
|texte= Statin use and Parkinson's disease in Denmark
}}
| This area was generated with Dilib version V0.6.23. |  |